KCM
MRSN

Kennedy Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Kennedy Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,211
Closed -$1.83M – 698
2023
Q2 		$1.83M Buy
22,211
+2,528
+13% +$370K 0.04% 479
2023
Q1 		$2.02M Buy
19,683
+2,124
+12% +$298K 0.06% 406
2022
Q4 		$2.57M Buy
17,559
+4,621
+36% +$781K 0.07% 386
2022
Q3 		$2.19M Buy
12,938
+9,402
+266% +$1.53M 0.06% 403
2022
Q2 		$408K Buy
+3,536
New +$333K 0.01% 556

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Kennedy Capital Management's MRSN Position: Q3 2023 in Review

Kennedy Capital Management sold out of Mersana Therapeutics (MRSN) in Q3 2023, closing a stake of 22,211 shares — an estimated $1.83M sold.

Kennedy Capital Management first reported a position in MRSN in Q2 2022 and held it in 5 quarters. The position peaked at $2.57M in Q4 2022. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • Kennedy Capital Management reported no remaining Mersana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Kennedy Capital Management sold 22,211 Mersana Therapeutics shares in Q3 2023, an estimated $1.83M.
  • Kennedy Capital Management first reported a position in Mersana Therapeutics in Q2 2022 and held it in 5 quarters.
  • Kennedy Capital Management's Mersana Therapeutics position peaked at $2.57M in Q4 2022.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on Kennedy Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.